Fundraising Fox

SeLux Diagnostics, Inc.

Charlestown, US · Founded 2014 · Delaware corporation · 1 known investors

Biotech

Founders & leadership

SeLux Diagnostics, Inc. was founded in 2014 by Eric Stern and Aleksandar Vacic.

ES
Eric SternCo-founder
AVAleksandar Vacic
Aleksandar VacicCo-founder
JP
James Parker CassidyNamed on SEC filing
SY
Scott YapheNamed on SEC filing
SE
Steven E. LufkinNamed on SEC filing
MR
Michael RubinNamed on SEC filing

Investors · 1

Sands Capital VenturesreportedArlington · $10M – $30Mvia Stephen P. Zachary · board

Reported raises · per SEC filings

Form D private placements

$124M disclosed across 6 rounds · 2018–2024

▶$40MraisedFeb 2024 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michele HealyExecutive Officer
  • Jamie CondieDirector
  • Orhan GazelleDirector
  • John WilsonExecutive Officer
  • Eric SternExecutive Officer, Director
  • Ingo ChakravartyDirector
  • Steven E. LufkinExecutive Officer, Director
  • James Parker CassidyDirector
  • Erich SchellerDirector
  • Adam SteelExecutive Officer
  • Aleksandar VacicExecutive Officer
Offering amount
$45M
Amount sold
$40M
First sale
Feb 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$48.2MraisedFeb 2022 · 25 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Scott YapheDirector
  • Aleksandar VacicExecutive Officer
  • James Parker CassidyDirector
  • Eric SternExecutive Officer, Director
  • Erich SchellerDirector
  • Jack PercoskieExecutive Officer
  • Steven E. LufkinExecutive Officer, Director
Offering amount
$57.6M
Amount sold
$48.2M
First sale
Feb 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.5MraisedJun 2021 · 25 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Steven E. LufkinExecutive Officer, Director
  • Parker CassidyDirector
  • Vacic AlexanderExecutive Officer
  • Stephen ZacharyDirector
  • Eric SternExecutive Officer, Director
  • Jack PercoskieExecutive Officer
  • Scott YapheDirector
Offering amount
$7.5M
Amount sold
$2.5M
First sale
Jun 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$813.9KraisedOct 2020 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Steven E. LufkinExecutive Officer, Director
  • Aleksandar VacicExecutive Officer, Promoter
  • Eric SternExecutive Officer, Director, Promoter
  • James Parker CassidyDirector
  • Stephen ZacharyDirector
  • Jack PercoskieExecutive Officer
  • Scott YapheDirector
Offering amount
$1.7M
Amount sold
$813.9K
First sale
Sep 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$9MraisedSep 2019 · 27 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Steven E. LufkinExecutive Officer, Director
  • Aleksandar VacicExecutive Officer, Promoter
  • Eric SternExecutive Officer, Director, Promoter
  • James Parker CassidyDirector
  • Scott YapheDirector
  • Stephen ZacharyDirector
Offering amount
$9M
Amount sold
$9M
First sale
Aug 2019
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$23.5MraisedApr 2018 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Eric SternExecutive Officer, Director, Promoter
  • James Parker CassidyDirector
  • Scott YapheDirector
  • Steven E. LufkinExecutive Officer, Director
  • Aleksandar VacicExecutive Officer, Promoter
  • Michael RubinDirector
Offering amount
$25M
Amount sold
$23.5M
First sale
Mar 2018
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Lucid Diagnostics3 shared keywordsLucid Diagnostics develops tests for the early detection of esophageal precancer using targeted next-generation sequencing, aimed at helping clinicians detect and treat the condition before it progresses to cancer. The company operates a CLIA-certified, CAP-accredited clinical lab licensed by the New York State Department of Health.

Companies competing with SeLux Diagnostics, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 4 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2021$2.8M
National Institutes of Health (NIH)National Institutes of HealthPhase II2019$1.8M
National Institutes of Health (NIH)National Institutes of HealthPhase I2018$298.9K
National Institutes of Health (NIH)National Institutes of HealthPhase I2016$216.5K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

SeLux Diagnostics Announces Milestone-Based Contract for U.S. HHS/BARDA Research Fundingprnewswire.com · Sep 2018

Frequently asked questions

Who founded SeLux Diagnostics, Inc.?
SeLux Diagnostics, Inc. was founded by Eric Stern, Aleksandar Vacic in 2014.
Who are SeLux Diagnostics, Inc.'s investors?
SeLux Diagnostics, Inc.'s investors include Sands Capital Ventures.
How much funding has SeLux Diagnostics, Inc. raised?
SeLux Diagnostics, Inc. has disclosed $124M raised across 6 rounds.
Where is SeLux Diagnostics, Inc. headquartered?
SeLux Diagnostics, Inc. is headquartered in Charlestown, US.